Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2023年度独立董事述职报告（钱跃竑）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and committee meetings, communication with shareholders, and oversight activities during the year 2023. The content focuses on the independent director's report on their responsibilities and activities rather than the full annual report or financial statements. It is a specific report related to board/management information, particularly about the independent director's role and performance. There is no indication that this is a full Annual Report (10-K), Audit Report (AR), or other financial filings. The document is not a brief announcement or a proxy solicitation but a detailed management-related report. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4496 characters) supports it being a substantive report rather than a short announcement.
2024-04-25 Chinese
江苏浩欧博生物医药股份有限公司2023年年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2023 annual profit distribution plan, detailing dividend per share, total dividend amount, and the approval process including board and supervisory meetings. It explicitly states that the profit distribution plan will be submitted to the 2023 annual general meeting for approval. The document does not contain full financial statements or comprehensive financial performance data, but rather focuses on dividend distribution details and procedural information. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder details. The document length is short (1591 characters), and it is not a full annual report or earnings release. Therefore, the appropriate classification is DIV with high confidence.
2024-04-25 Chinese
江苏浩欧博生物医药股份有限公司董事会对独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the independence of its independent directors. It references regulatory guidelines related to independent directors and confirms their compliance with independence requirements. The content is focused on governance and board-related information rather than financial results, audit, or shareholder voting. The document length is short (433 characters), and it is a formal report on board/management matters, specifically about director independence. Therefore, the most appropriate classification is Board/Management Information (MANG).
2024-04-25 Chinese
江苏浩欧博生物医药股份有限公司第三届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the company's 2023 annual report, financial statements, audit firm reappointment, profit distribution plan, and other governance matters. The document repeatedly states that these proposals will be submitted to the 2023 annual shareholders' meeting for approval. It references the 2023 annual report and other related documents but does not contain the full annual report or detailed financial statements itself. The document length is 3408 characters, which is relatively short and consistent with an announcement rather than a full report. The content is primarily about the Supervisory Board's meeting resolutions and approvals, not the full annual report or financial data. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals related to the annual report and other corporate governance matters, but it is not the annual report itself or a direct financial report.
2024-04-25 Chinese
信会师报字[2024]第ZA11957号 江苏浩欧博生物医药股份有限公司募集资金存放与使用情况专项报告的鉴证报告
Audit Report / Information Classification · 100% confidence The document is titled as a "鉴证报告" (Assurance Report) on the "募集资金存放与使用情况专项报告" (Special Report on the Deposit and Use of Raised Funds) for the year 2023 by 江苏浩欧博生物医药股份有限公司. It is issued by a certified public accounting firm (立信会计师事务所) and includes detailed verification of the company's compliance with regulatory requirements on the management and use of raised funds. The document contains detailed financial data on the raised funds, their usage, management, and related agreements, as well as the auditor's assurance conclusion. This is a standalone audit/assurance report focused on a specific regulatory requirement related to fundraising funds usage, not a full annual report or interim report. It is not an announcement or a brief summary but a full assurance report. Therefore, it fits the category of Audit Report / Information (AR). FY 2023
2024-04-25 Chinese
信会师报字[2024]第ZA11956号 江苏浩欧博生物医药股份有限公司内部控制审计报告
Regulatory Filings
2024-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.